Skip to main content
. 2019 Mar 23;8(7):e010860. doi: 10.1161/JAHA.118.010860

Figure 4.

Figure 4

Administration of TLR9 antagonist attenuates atherogenesis and vascular inflammation in Apoe −/− mice. A, En face Sudan IV staining of the aortic arch showed that administration of iODN2088, an inhibitory oligonucleotide for TLR9, to Ang II–infused Apoe −/− mice reduced atherosclerotic lesion development compared with control oligonucleotide administration, Ctrl‐iODN (n=7–8). Bar: 1 mm. B, qPCR analysis using abdominal aorta revealed that iODN2088 treatment decreased the expression of inflammatory molecules such as VCAM‐1, ICAM‐1, and MCP‐1. TLR9 deletion also reduced the expression of F4/80, a macrophage marker, and TNF‐α in the atherosclerotic aorta (n=7–8). *P<0.05 and **P<0.01. All comparisons between iODN2088‐treated group and Ctrl‐iODN–treated group were performed with Mann–Whitney U test. All values are mean±SEM. ICAM‐1 indicates intercellular cell adhesion molecule‐1; MCP‐1, monocyte chemoattractant protein‐1; qPCR, quantitative real‐time polymerase chain reaction; TLR9, Toll‐like receptor 9; TNF‐ α, tumor necrosis factor‐α; VCAM‐1, vascular cell adhesion molecule‐1.